iSonea FPO
(ASX:ISN) says its ready to begin shopping its Acoustic Respiratory Measurement technology to the big drug companies.
The technology, which is employed in the company’s AirSonea asthma devices, has been validated across a number of independent clinical studies.
The device and app technology can be used wirelessly in home devices and smartphones to detect and measure wheeze in asthma sufferers. It’s particularly useful for companies trying to develop treatments for preschool children.
The technology is also offered to pharmaceutical companies developing their own respiratory treatments.
iSonea made a net loss of $3.04 million for the first half of the 2015 financial year.
